Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Sébastien Anguille"'
Autor:
Sébastien Anguille, Herman Goossens, Johan M.J. Van den Bergh, Tessa Kerre, Zwi N. Berneman, Marc Peeters, Evelien Smits, Carlo Heirman, Viggo Van Tendeloo, Sarah Bonte, Kris Thielemans, Barbara Stein, Yannick Willemen
Publikováno v:
Oncotarget
ONCOTARGET
ONCOTARGET
We formerly demonstrated that vaccination with Wilms tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we coul
Autor:
Yannick Willemen, Zwi N. Berneman, Eva Lion, Heleen H. Van Acker, Johan M.J. Van den Bergh, Viggo Van Tendeloo, Evelien Smits, Sébastien Anguille
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-13 (2016)
Journal of Hematology & Oncology
Journal of hematology and oncology
Journal of Hematology & Oncology
Journal of hematology and oncology
Background Adoptive immunotherapy is gaining momentum to fight malignancies, whereby γδ T cells have received recent attention as an alternative cell source as to natural killer cells and αβ T cells. The advent of γδ T cells is largely due to t
Autor:
Viggo Van Tendeloo, Heleen H. Van Acker, Carl G. Figdor, Johan M.J. Van den Bergh, Barbara Stein, Eva Lion, Marc Peeters, Steven Heynderickx, Zwi N. Berneman, Sébastien Anguille, Vicky A. E. Roelandts, I. Jolanda M. de Vries, Gosse J. Adema, Evelien Smits, Yannick Willemen
Publikováno v:
Cancer immunology and immunotherapy
Cancer Immunology Immunotherapy, 64, 831-42
Cancer Immunology Immunotherapy, 64, 7, pp. 831-42
Cancer Immunology Immunotherapy, 64, 831-42
Cancer Immunology Immunotherapy, 64, 7, pp. 831-42
Contains fulltext : 155181.pdf (Publisher’s version ) (Open Access) Dendritic cell (DC) vaccination has demonstrated potential in clinical trials as a new effective cancer treatment, but objective and durable clinical responses are confined to a mi
Autor:
I. Vandenbosch, Wilfried Schroyens, Anke Verlinden, Zwi N. Berneman, A. Gadisseur, Elke Smits, A. Van de Velde, K. Saevels, Sébastien Anguille
Publikováno v:
HemaSphere. 3:556
Autor:
Zwi N. Berneman, Paul Germonpré, B. Op de Beeck, Marc Peeters, Annemiek Snoeckx, Elke Smits, A. Van de Velde, Eva Lion, Griet Nijs, Viggo Van Tendeloo, Yannick Willemen, A Van Driessche, Nathalie Cools, Manon T. Huizing, Barbara Stein, L. Rutsaert, Katrien Vermeulen, Sébastien Anguille, K. Saevels
Publikováno v:
Cytotherapy. 21:S10
Background & Aim Dendritic cells (DC) have the capacity to induce potent tumor antigen-specific T-cell immunity. We have completed vaccination in the adjuvant setting in 77 cancer patients (acute myeloid leukemia (AML, n=30), metastatic breast cancer
Autor:
Yannick Willemen, Evelien Smits, Johan M.J. Van den Bergh, Eva Lion, Viggo Van Tendeloo, Zwi N. Berneman, Sébastien Anguille, Heleen H. Van Acker
Publikováno v:
Human vaccines & immunotherapeutics
Owing to their professional antigen-presenting capacity and unique potential to induce tumor antigen-specific T cell immunity, dendritic cells (DCs) have attracted much interest over the past decades for therapeutic vaccination against cancer. Clinic
Autor:
Herman Goossens, Wilfried Schroyens, S. Dom, Philippe Beutels, Zwi N. Berneman, Anke Verlinden, I. Cornille, Evelien Smits, Griet Nijs, Viggo Van Tendeloo, A. Gadisseur, Sébastien Anguille, A. Van de Velde
Publikováno v:
Leukemia research
The advent of new cell-based immunotherapies for leukemia offers treatment possibilities for certain leukemia subgroups. The wider acceptability of these new technologies in clinical practice will depend on its impact on survival and costs. Due to th
Autor:
Zwi N. Berneman, Yannick Willemen, Griet Nijs, Barbara Stein, Eva Lion, Evelien Smits, Viggo Van Tendeloo, Sébastien Anguille
Publikováno v:
Methods in Molecular Biology ISBN: 9781493933365
First described in the 1970s, dendritic cells (DC) are currently subjects of intense investigation to exploit their unique antigen-presenting and immunoregulatory capacities. In cancer, DC show promise to elicit or amplify immune responses directed a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d9289736465b49ca8e1c9b04cb047b4
https://doi.org/10.1007/978-1-4939-3338-9_3
https://doi.org/10.1007/978-1-4939-3338-9_3
Autor:
Viggo Van Tendeloo, Sébastien Anguille, Evelien Smits, Zwi N. Berneman, Yannick Willemen, Eva Lion
Publikováno v:
Leukemia
Interferon-α (IFN-α), a type I IFN, is a well-known antitumoral agent. The investigation of its clinical properties in acute myeloid leukemia (AML) has been prompted by its pleiotropic antiproliferative and immune effects. So far, integration of IF
Autor:
Heleen H. Van Acker, Evelien Smits, Yannick Willemen, Sébastien Anguille, Viggo Van Tendeloo
Publikováno v:
Pharmacology and therapeutics
A growing body of evidence points toward an important anti-cancer effect of bisphosphonates, a group of inexpensive, safe, potent, and long-term stable pharmacologicals that are widely used as osteoporosis drugs. To date, they are already used in the